Healthcare Leaders Support FTC’s Second Report on PBMs, While PBMs Criticize Findings

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs, highlighting substantial price markups by PBMs on medications for cancer, HIV and other conditions. The post Healthcare Leaders Support FTC’s…

Read More

Ain’t no shame in the heart of VC

By MATTHEW HOLT It’s JPM week. That means a ton of startup bros wandering around San Francisco wondering who all the biotech guys and investment banker greyhairs are and why they’re still wearing suits. Unlikely to be wearing suits are the digital health kids and the VCs they are trying to hunt down. The glory…

Read More

Key Facts on Health Coverage of Immigrants

This fact sheet provides an overview of health coverage for immigrants based on data from the 2023 KFF/LA Times Survey of Immigrants, the largest nationally representative survey focused on immigrants and discusses potential implications of incoming Trump administration policies for coverage of immigrants.

Read More

Overview of existing taxonomies of pricing and payment scheme

What options do payers have for setting prices for high-cost drugs? Examples include volume discounts, performance based contracts and coverage with evidence. However, is there a comprehensive taxonomy one can use for defining all these different pricing and payment options? The closest we have come is a new paper by Ardito, Ciani & Drummond (2024)….

Read More